Saliva Diagnostics delists from Nasdaq:
This article was originally published in Clinica
Saliva Diagnostics has left the Nasdaq SmallCap market because it says it does not meet the new listing standards required by the market. The rapid diagnostics company plans to have itself listed on the OTC Bulletin Board in the near future. The company recently completed a private placement of 6% preferred stock at $1.5 million which is convertible into ordinary shares at the end of April.